These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 28272724)
1. [Magnetic resonance imaging with gadolinium in the acute phase of relapses in multiple sclerosis]. Ortiz P; Bareno J; Cabrera L; Rueda K; Rovira A Rev Neurol; 2017 Mar; 64(6):241-246. PubMed ID: 28272724 [TBL] [Abstract][Full Text] [Related]
2. Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations. Then Bergh F; Kümpfel T; Schumann E; Held U; Schwan M; Blazevic M; Wismüller A; Holsboer F; Yassouridis A; Uhr M; Weber F; Daumer M; Trenkwalder C; Auer DP BMC Neurol; 2006 May; 6():19. PubMed ID: 16719908 [TBL] [Abstract][Full Text] [Related]
3. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Thorpe JW; Kidd D; Moseley IF; Kenndall BE; Thompson AJ; MacManus DG; McDonald WI; Miller DH Neurology; 1996 Feb; 46(2):373-8. PubMed ID: 8614497 [TBL] [Abstract][Full Text] [Related]
4. MRI as an outcome in multiple sclerosis clinical trials. Daumer M; Neuhaus A; Morrissey S; Hintzen R; Ebers GC Neurology; 2009 Feb; 72(8):705-11. PubMed ID: 19073945 [TBL] [Abstract][Full Text] [Related]
5. Plasma exchange in severe acute relapses of multiple sclerosis - Results from a Portuguese cohort. Correia I; Ribeiro JJ; Isidoro L; Batista S; Nunes C; Macário C; Borges C; Tomaz J; Sousa L Mult Scler Relat Disord; 2018 Jan; 19():148-152. PubMed ID: 29241141 [TBL] [Abstract][Full Text] [Related]
6. The contemporary role of MRI in the monitoring and management of people with multiple sclerosis in the UK. Fernandes L; Allen CM; Williams T; Tallantyre E; Evangelou N; Chataway J; Ford HL; Mult Scler Relat Disord; 2021 Oct; 55():103190. PubMed ID: 34365316 [TBL] [Abstract][Full Text] [Related]
7. ENT-MS-12 questionnaire: A novel tool to investigate otolaryngology symptoms in patients with relapsing-remitting multiple sclerosis. Results from a pilot study. Di Stadio A; Ralli M; Altieri M; Brenner MJ; Dipietro L; Messineo D; Kaski D; Bernitsas E Mult Scler Relat Disord; 2021 Jan; 47():102660. PubMed ID: 33291034 [TBL] [Abstract][Full Text] [Related]
8. Predictors of relapse rate in MS clinical trials. Held U; Heigenhauser L; Shang C; Kappos L; Polman C; Neurology; 2005 Dec; 65(11):1769-73. PubMed ID: 16344520 [TBL] [Abstract][Full Text] [Related]
9. A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Jeffery DR; Chepuri N; Durden D; Burdette J Mult Scler; 2005 Jun; 11(3):296-301. PubMed ID: 15957510 [TBL] [Abstract][Full Text] [Related]
10. Cortical relapses in multiple sclerosis. Puthenparampil M; Poggiali D; Causin F; Rolma G; Rinaldi F; Perini P; Gallo P Mult Scler; 2016 Aug; 22(9):1184-91. PubMed ID: 25791367 [TBL] [Abstract][Full Text] [Related]
14. Human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis: a randomized, placebo-controlled, multiple-dose study. Lublin FD; Bowen JD; Huddlestone J; Kremenchutzky M; Carpenter A; Corboy JR; Freedman MS; Krupp L; Paulo C; Hariri RJ; Fischkoff SA Mult Scler Relat Disord; 2014 Nov; 3(6):696-704. PubMed ID: 25891548 [TBL] [Abstract][Full Text] [Related]
15. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B; Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766 [TBL] [Abstract][Full Text] [Related]
16. Poor PASAT performance correlates with MRI contrast enhancement in multiple sclerosis. Bellmann-Strobl J; Wuerfel J; Aktas O; Dörr J; Wernecke KD; Zipp F; Paul F Neurology; 2009 Nov; 73(20):1624-7. PubMed ID: 19917984 [TBL] [Abstract][Full Text] [Related]
17. Management of worsening multiple sclerosis with mitoxantrone: a review. Fox EJ Clin Ther; 2006 Apr; 28(4):461-74. PubMed ID: 16750460 [TBL] [Abstract][Full Text] [Related]
18. Elevated plasma fibrinogen levels in multiple sclerosis patients during relapse. Miranda Acuña J; Hidalgo de la Cruz M; Ros AL; Tapia SP; Martínez Ginés ML; de Andrés Frutos CD Mult Scler Relat Disord; 2017 Nov; 18():157-160. PubMed ID: 29141800 [TBL] [Abstract][Full Text] [Related]
19. Multiple sclerosis lesion formation and early evolution revisited: A weekly high-resolution magnetic resonance imaging study. Guttmann CR; Rousset M; Roch JA; Hannoun S; Durand-Dubief F; Belaroussi B; Cavallari M; Rabilloud M; Sappey-Marinier D; Vukusic S; Cotton F Mult Scler; 2016 May; 22(6):761-9. PubMed ID: 26362901 [TBL] [Abstract][Full Text] [Related]
20. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]